Erratum: Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance (Journal of Medicinal Chemistry (2010) 53 (8116) DOI: 10.1021/jm101010n);Synthesis and discovery of water-soluble microtubule targeting agents that bind to the colchicine site on tubulin and circumvent Pgp mediated resistance

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8116-8128

  Gangjee, Aleem ^a   Zhao, Ying ^a   Lin, Lu ^a   Raghavan, Sudhir ^a   Roberts, Elizabeth G ^b   Risinger, April L ^b   Hamel, Ernest ^c   Mooberry, Susan L ^b  

^a DUQUESNE UNIVERSITY   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COLCHICINE; GLYCOPROTEIN P; N (2 METHOXYPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; N (3 METHOXYPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; N (4 METHOXYPHENYL) 2 METHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) 2,6 DIMETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2 DIMETHYL 7H PYRROLO[2,3 D]PYRIMIDIN 4 AMINE; N (4 METHOXYPHENYL) N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; N PHENYL N,2,6 TRIMETHYL 6,7 DIHYDRO 5H CYCLOPENTA[D]PYRIMIDIN 4 AMINIUM CHLORIDE; PACLITAXEL; PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CHLORINATION; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG DESIGN; DRUG SYNTHESIS; IC 50; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING; POLYMERIZATION;

EID: 78649509037     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm101533s     Document Type: Erratum

References (59)

1. Jordan, M. A.; Wilson, L. Microtubules as a Target for Anticancer Drugs Nat. Rev. Cancer 2004, 4, 253-265
2. Jordan, M. A.; Kamath, K. How do Microtubule-Targeted Drugs Work? An Overview Curr. Cancer Drug Targets 2007, 7, 730-742
3. Lee, J. F.; Harris, L. N. Antimicrotubule Agents. In Cancer: Principles & Practice of Oncology, 8 th ed.; DeVita, V. T., Jr.; Lawrence, T. S.,; Rosenberg, S. A., Eds.; Lippincott Williams & Wilkins: Philadelphia, PA, 2008; pp 447 - 456.
4. Löwe, J.; Li, H.; Downing, K. H.; Nogales, E. Refined Structure of αβ-Tubulin at 3.5Å Resolution J. Mol. Biol. 2001, 313, 1045-1057
5. Huey, R. M.; Calvo, E.; Barasoain, I.; Pineda, O.; Edler, M. C.; Matesanz, R.; Cerezo, G.; Vanderwal, C. D.; Day, B. W.; Sorensen, E. J.; Lopez, J. A.; Andreu, J. M.; Hamel, E.; Diaz, J. F. Cyclostreptin Binds Covalently to Microtubule Pores and Lumenal Taxoid Binding Sites Nat. Chem. Biol. 2007, 3, 117-125
6. Kanthou, C.; Tozer, M. T. Microtubule Depolymerizing Vascular Disrupting Agents: Novel Therapeutic Agents for Oncology and Other Pathologies Int. J. Exp. Pathol. 2009, 90, 284-294
7. Carlson, R. O. New Tubulin Targeting Agents Currently in Clinical Development Expert Opin. Investig. Drugs 2008, 17, 707-722
8. O'Connor, P. M.; Jackman, J.; Bae, I.; Myers, T. G.; Fan, S.; Mutoh, M.; Scudiero, D. A.; Monks, A.; Sausville, E. A.; Weinstein, J. N.; Friend, S.; Fornace, A. J., Jr.; Kohn, K. W. Characterization of the p53 Tumor Suppressor Pathway in Cell Lines of the National Cancer Institute Anticancer Drug Screen and Correlations with the Growth-inhibitory Potency of 123 Anticancer Agents Cancer Res. 1997, 57, 4285-4300
9. Risinger, A. L.; Giles, F. J.; Mooberry, S. L. Microtubule Dynamics as a Target in Oncology Cancer Treat. Rev. 2008, 35, 255-261
10. Hamel, E. An Overview of Compounds That Interact With tubulin and their Effects on Microtubule Assembly. In The Role of Microtubules in Cell Biology, Neurobiology and Oncology; Fojo, T., Ed.; Humana Press: Totowa, NJ, 2008; pp 1 - 19.
11. Ling, V. Multidrug Resistance: Molecular Mechanisms and Clinical Relevance Cancer Chemother. 1997, 40, S3-8
12. Leonard, G. D.; Fojo, T.; Bates, S. E. The Role of ABC Transporters in Clinical Practice Oncologist 2003, 8, 411-424
13. Yeh, J. J.; Hsu, W. H.; Wang, J. J.; Ho, S. T.; Kao, A. Predicting Chemotherapy Response to Taxol-based Therapy in Advanced Non-Small-Cell Lung Cancer with P-glycoprotein Expression Respiration 2003, 70, 32-35
14. Chiou, J. F.; Liang, J. A.; Hsu, W. H.; Wang, J. J.; Ho, S. T.; Kao, A. Comparing the Relationship of Taxol-based Chemotherpay Response with P-glycoprotein and Lung Resistance-related Protein Expression in Non-Small Cell Lung Cancer Lung 2003, 181, 267-273 (Pubitemid 37323734)
15. Nooter, K.; Westerman, A. M.; Flens, M. J.; Zaman, G. J.; Scheper, R. J.; van Wingerden, K. E.; Burger, H.; Oostrum, R.; Boersma, T.; Sonneveld, P. Expression of the Multidrug Resistance-Associated Protein (MRP) Gene in Human Cancers Clin. Cancer Res. 1995, 1, 1301-1310
16. Fojo, T.; Menefee, M. Mechanisms of Multidrug Resistance: The Potential Role of Microtubule-stabilizing Agents Ann. Oncol. 2007, 18, 3-8
17. Rosell, R.; Scagliotti, G.; Danenberg, K. D.; Lord, R. V. N.; Bepler, G.; Novello, S.; Cooc, J.; Crino, L.; Sanchez, J. J.; Taron, M.; Boni, C.; De Marinis, F.; Tonato, M.; Marangolo, M.; Gozzelino, F.; Di Costanzo, F.; Rinaldi, M.; Salonga, D.; Stephens, C. Transcripts in Pretreatment Biopsies From A Three-Arm Randomized Trial In Metastatic Non-Small-Cell Lung Cancer Oncogene 2003, 22, 3548-3553
18. Dumontet, C.; Isaac, S.; Souquet, P.-J.; Bejui-Thivolet, F.; Pacheco, Y.; Peloux, N.; Frankfurter, A.; Luduena, R.; Perol, M. Expression of Class III Beta Tubulin In Non-Small Cell Lung Cancer Is Correlated With Resistance To Taxane Chemotherapy Bull. Cancer 2005, 92, E25-30
19. Seve, P.; Isaac, S.; Tredan, O.; Souquet, P.-J.; Pacheco, Y.; Perol, M.; Lafanechere, L.; Penet, A.; Peiller, E.-L.; Dumontet, C. Expression of Class III β -Tubulin Is Predictive of Patient Outcome in Patients with Non-Small Cell Lung Cancer Receiving Vinorelbine-Based Chemotherapy Clin. Cancer Res. 2005, 11, 5481-5486 (Pubitemid 41060824)
20. Tommasi, S.; Mangia, A.; Lacalamita, R.; Bellizzi, A.; Fedele, V.; Chiriatti, A.; Thomssen, C.; Kendzierski, N.; Latorre, A.; Lorusso, V.; Schittulli, F.; Zito, F.; Kavallaris, M.; Paradiso, A. Cytoskeleton and Paclitaxel Sensitivity In Breast Cancer: The Role Of Beta-Tubulins Int. J. Cancer 2007, 120, 2078-2085
21. Mozzetti, S.; Ferlini, C.; Concolino, P.; Filippetti, F.; Raspaglio, G.; Prislei, S.; Gallo, D.; Martinelli, E.; Ranelletti, F. O.; Ferrandina, G.; Scambia, G. Class III β-tubulin Overexpression Is A Prominent Mechanism Of Paclitaxel Resistance In Ovarian Cancer Patients Clin. Cancer Res. 2005, 11, 298-305
22. Ferrandina, G.; Zannoni, G. F.; Martinelli, E.; Paglia, A.; Gallotta, V.; Mozzetti, S.; Scambia, G.; Ferlini, C. Class III β -Tubulin Overexpression Is A Marker Of Poor Clinical Outcome In Advanced Ovarian Cancer Patients Clin. Cancer Res. 2006, 12, 2774-2779
23. Seve, P.; Dumontet, C. Is Class III β-Tubulin a Predictive Factor in Patients Receiving Tubulin-binding Agents? Lancet Oncol. 2008, 9, 168-175
24. Strengel, C; Newman, S. P.; Lesse, M. P.; Potter, B. V. L.; Reed, M. J.; Purohit, A. Class III Beta- Tubulin Expression and in vitro Resistance To Microtubule Targeting Agents Br. J. Cancer 2010, 102, 316-324
25. Lee, L.; Robb, L. M.; Lee, M.; Davis, R.; Mackay, H.; Chavda, S.; O'Brien, E. L.; Risinger, A. L.; Mooberry, S. L.; Lee, M. Design, Synthesis and Biological Evaluations of 2,5-Diaryl-2,3-dihydro-1,3,4-oxadiazoline Analogs of Combretastatin-A4 J. Med. Chem. 2010, 53, 325-334
26. Dumontet, C.; Jordan, M. A.; Lee, F. F. Y. Ixabepilone: Targeting βIII-Tubulin Expression in Taxane-resistant Malignancies Mol. Cancer Ther. 2009, 8, 17-25
27. Speicher, L. A.; Barone, L; Tew, K. D. Combined Antimicrotubule Activity of Estramustine and Taxol in Human Prostate Carcinoam Cell lines Cancer Res. 1992, 52, 4433-4440
28. Giannakakou, P.; Villalba, L.; Li, H.; Poruchynsky, M.; Fojo, T. Combinations of Paclitaxel and Vinblastine and Their Effects on Tubulin Polymerization and Cellular Cytotoxicity: Characterization of a Synergistic Schedule Int. J. Cancer 1998, 75, 57-63
29. Shi, W.; Horsman, M. R.; Siemann, D. W. Combined Modality Approaches Using Vasculature-disrupting Agents. In Vascular-Targeted Therapies in Oncology; Siemann, D. W., Ed.; J. Wiley & Sons, Ltd.: West Sussex, England, 2006; pp 123 - 136 and other chapters in the text.
30. Gangjee, A.; Zhao, Y.; Ihnat, M. A.; Green, D.; Miller, W. T. Synthesis of 2-Amino-4- m -bromoanilino-6-arylmethyl-7 H -pyrrolo[2,3- d ]pyrimidines as Tyrosine Kinase Inhibitors and Antiangiogenic Agents. Presented at the 96th American Association for Cancer Research (AACR) Annual Meeting, Anaheim, CA, April 16-20, 2005. Poster No. 3946.
31. Gangjee, A.; Zhao, Y.; Raghavan, S.; Ihnat, M. A.; Disch, B. C. Design, Synthesis and Evaluation of 2-Amino-4- m -bromoanilino-6-arylmethyl- 7H -pyrrolo[2,3- d ]pyrimidines as Tyrosine Kinase Inhibitors and Antiangiogenic Agents Bioorg. Med. Chem. 2010, 18, 5261-5273
32. Bai, R.; Paull, K. D.; Herald, C. L.; Pettit, G. R.; Hamel, E. Halichondrin B and Homohalichondrin B, Marine Natural Products Binding in the Vinca Domain of Tubulin. Discovery of Tubulin-based Mechanism of Action by Analysis of Differential Cytotoxicity Data J. Biol. Chem. 1991, 266, 15882-15889
33. Paull, K. D.; Lin, C. M.; Malspeis, L.; Hamel, E. Identification of Novel Antimitotic Agents Acting at the Tubulin Level by Computer-assisted Evaluation of Differential Cytotoxicity Data Cancer Res. 1992, 52, 3892-3900
34. Paull, K. D.; Hamel, E.; Malspeis, L. The Prediction of Biochemical Mechanism of Action From the in vivo Antitumor Screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents; Foye, W. O., Ed.; American Chemical Society: Washington, DC, 1995; pp 9 - 45.
35. West, R. A.; Beauchamp, L. 2-Alkyl(aryl)- and 2,7-Dimethyl-4-substituted Aminopyrrolo [2,3- d ] pyrimidines J. Org. Chem. 1961, 26, 3809-3812
36. Ohno, S.; Mizukoshi, K.; Komatsu, O.; Kuno, Y.; Nakamura, Y.; Kato, E.; Nagasaka, M. Synthesis and Hypoglycemic Activity of 7,8-Dihydro-6H-thiopyrano[3, 2- d ]pyrimidine Derivatives and Related Compounds Chem. Pharm. Bull. 1986, 34, 4150-4165
37. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
38. Boyd, M. R.; Paull, K. D. Some Practical Considerations and Applications of the National Cancer Institute in vitro Anticancer Discovery Screen Drug Dev. Res. 1995, 34, 91-109
39. Risinger, A. L.; Jackson, E. M.; Polin, L. A.; Helms, G. L.; LeBoeuf, D. A.; Joe, P. A.; Hopper-Borge, E; Ludueña, R. F.; Kruh, G. D.; Mooberry, S. L. The Taccalonolides: Microtubule Stabilizers that Circumvent Clinically Relevant Taxane Resistance Mechanisms Cancer Res. 2008, 68, 8881-8888
40. Ravelli, R. B. G.; Gigant, B.; Curmi, P. A.; Jourdain, I.; Lachkar, S.; Sobel, A.; Knossow, M. Insight into Tubulin Regulation from a Complex with Colchicine and a Stathmin-like Domain Nature 2004, 428, 198-202
41. Nguyen, T. L.; McGrath, C.; Hermone, A. R.; Burnett, J. C.; Zaharevitz, D. W.; Day, B. W.; Wipf, P.; Hamel, E.; Gussio, R. A Common Pharmacophore for a Diverse Set of Colchicine Site Inhibitors Using a Structure-based Approach J. Med. Chem. 2005, 48, 6107-6116
42. Bhattacharyya, B.; Panda, D.; Gupta, S.; Banerjee, M. Anti-Mitotic Activity of Colchicine and the Structural Basis for its Interaction with Tubulin Med. Res. Rev. 2008, 28, 155-183
43. Molecular Operating Environment (MOE 2008.10); Chemical Computing Group, Inc.: Montreal, Quebec, Canada, 2008; www.chemcomp.com.
44. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C. Arylthioindoles, Potent Inhibitors of Tubulin Polymerization J. Med. Chem. 2004, 47, 6120-6123
45. Gangjee, A.; Devraj, R.; McGuire, J. J.; Kisliuk, R. L. 5-Arylthio Substituted 2-Amino-4-oxo-6-methylpyrrolo[2,3- d ]pyrimidine Antifolates as Thymidylate Synthase Inhibitors and Antitumor Agents J. Med. Chem. 1995, 38, 4495-4502
46. Gangjee, A.; Vasudevan, A.; Kisliuk, R. L. Nonclassical 5-Substituted Tetrahydroquinazolines as Potential Inhibitors of Thymidylate Synthase J. Heterocycl. Chem. 1997, 34, 1669-1676
47. Gangjee, A.; Mavandadi, F.; Kisliuk, R. L.; Queener, S. F. Synthesis of Classical and a Nonclassical 2-Amino-4-oxo-6-methyl-5-substituted Pyrrolo[2,3- d ]pyrimidine Antifolate Inhibitors of Thymidylate Synthase J. Med. Chem. 1999, 42, 2272-2279
48. Gangjee, A.; Jain, H. D.; McGuire, J. J.; Kisliuk, R. L. Benzoyl Ring Halogenated Classical 2-Amino-6-methyl-3,4-dihydro-4-oxo-5-substituted Thiobenzoyl-7 H -pyrrolo[2,3- d ]pyrimidine Antifolates as Inhibitors of Thymidylate Synthase and as Antitumor Agents J. Med. Chem. 2004, 47, 6730-6739
49. Gangjee, A.; Li, W.; Yang, J.; Kisliuk, R. L. Design, Synthesis, and Biological Evaluation of Classical and Nonclassical 2-Amino-4-oxo-5-substituted- 6-methylpyrrolo[3,2- d ]pyrimidines as Dual Thymidylate Synthase and Dihydrofolate Reductase Inhibitors J. Med. Chem. 2008, 51, 68-76
50. Webber, S. J.; Bleckman, T. M.; Attard, J.; Deal, J. G.; Kathardekar, V.; Welsh, K. M.; Webber, S.; Janson, C. A.; Matthews, D. A. Design of Thymidylate Synthase Inhibitors Using Protein Crystal Structures: The Synthesis and Biological Evaluation of a Novel Class of 5-Substituted Quinazolinones J. Med. Chem. 1993, 36, 733-746
51. Sybyl X 1.1; Tripos, Inc.: St. Louis, MO, 2010.
52. Kasibhatla, S.; Baichwal, V.; Cai, S. X.; Roth, B.; Skvortsova, I.; Skvortsov, S.; Lukas, P.; English, N. M.; Sirisoma, N.; Drewe, J.; Pervin, A.; Tseng, B.; Carlson, R. O.; Pleiman, C. M. MPC-6827: A Small Molecule Inhibitor of Microtubule Formation that is not a Substrate for Multidrug Resistance Pumps Cancer Res. 2007, 67, 5865-5871
53. Sirisoma, N.; Kasibhatla, S.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M.; Baichwal, V.; Mather, G. G.; Jessing, K.; Hussain, R.; Hoang, K.; Pleiman, C. M.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 2-Chloro- N -(4-methoxyphenyl)- N -methylquinazolin-4-amine (EP128265, MPI-0441138) as a Potent Inducer of Apoptosis with High In Vivo Activity J. Med. Chem. 2008, 51, 4771-4779
54. Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M.; Mather, G. G.; Pleiman, C. M.; Kasibhatla, S.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of N -(4-Methoxyphenyl)- N,2-dimethylquinazolin-4- amine, a Potent Apoptosis Inducer and Efficacious Anticancer Agent with High Blood Brain Barrier Penetration J. Med. Chem. 2009, 52, 2341-2351
55. Sirisoma, N.; Pervin, A.; Zhang, H.; Jiang, S.; Willardsen, J. A.; Anderson, M.; Mather, G. G.; Pleiman, C. M.; Kasibhatla, S.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of N -methyl-4-(4-methoxyanilino) quinazolines as Potent Apoptosis Inducers. Structure-Activity Relationship of the Quinazoline Ring Bioorg. Med. Chem. Lett. 2010, 20, 2030-2334
56. Kemnitzer, W.; Sirisoma, N.; May, C.; Tseng, B.; Drewe, J.; Cai, S. X. Discovery of 4-Anilino-N-methylthieno[3,2- d ]pyrimidines and 4-Anilino-N-methylthieno[2,3-d]pyrimidines as Potent Apoptosis Inducers Bioorg. Med. Chem. Lett. 2009, 19, 3536-3540
57. Hamel, E.; Lin, C. M. Separation of Active Tubulin and Microtubule-associated Proteins by Ultracentrifugation and Isolation of a Component Causing the Formation of Microtubule bundles Biochemistry 1984, 23, 4173-4184
58. Hamel, E. Evaluation of Antimitotic Agents by Quantitative Comparisons of Their Effects on the Polymerization of Purified Tubulin Cell Biochem. Biophys. 2003, 38, 1-22
59. Verdier-Pinard, P.; Lai, J.-Y.; Yoo, H.-D.; Yu, J.; Márquez, B.; Nagle, D. G.; Nambu, M.; White, J. D.; Falck, J. R.; Gerwick, W. H.; Day, B. W.; Hamel, E. Structure-Activity Analysis of the Interaction of Curacin a, the Potent Colchicine Site Antimitotic Agent, with Tubulin and Effects of Analogs on the Growth of MCF-7 Breast Cancer Cells Mol. Pharmacol. 1998, 53, 62-76